CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...

Widespread deployment of embolic protection devices is hampered by the need for specific knowledge and training. For these devices to properly catch embolic debris during complex cardiovascular ...

The FiberNet Embolic Protection System is a temporary, intravascular, 0.014-inch wire-based filter system that is placed distal to a lesion to be treated by interventional procedures (Figures 1 & 2).

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

SANTA ROSA, Calif.--(BUSINESS WIRE)--Claret Medical® today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Sentinel™ Cerebral Protection ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

Please provide your email address to receive an email when new articles are posted on . Adults who underwent transcatheter aortic valve replacement with a cerebral protection system experienced fewer ...

Debris from the proximal filter of the Sentinel system, including valve tissue, arterial wall with acute thrombus, calcification, and myocardium (Photo Credit: Aloke Finn) In a small, prospective ...

United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...

(MENAFN- GlobeNewsWire - Nasdaq) Key states, including California and Texas, lead in demand due to advanced healthcare systems and aging populations Dublin, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The ...